Application of kavain in preparing drug for treating osteoporosis

A technology for osteoporosis and buckwheat, which is used in drug combinations, bone diseases, etc.

Inactive Publication Date: 2018-10-23
GUANGXI MEDICAL UNIVERSITY
View PDF3 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The effect of Kavain on bone homeostasis, especially on osteoclast and osteoblast differentiation has not been reported

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of kavain in preparing drug for treating osteoporosis
  • Application of kavain in preparing drug for treating osteoporosis
  • Application of kavain in preparing drug for treating osteoporosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0020] 1. Materials

[0021] 1. Materials

[0022]Alpha Modified Minimal Essential Medium (α-MEM) and Fetal Bovine Serum (FBS) were purchased from Thermo Fisher Scientific (Scoresby, Australia). Kavain was extracted and purified by Tan Renxiang's research team at Nanjing University, and stored at a concentration of 1mM in phosphate buffer solution. Anti-integrin-β3, MMP 9, DC-STAMP, ctsk, nfATc 1, iκB-α, erk, ink, p38, ph antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). (P) Preparation references of ERK, p-p38, p-JNK and β-actin, V-ATPase D2 antibodies (Feng H, Cheng T, Steer JH, Joyce DA, Pavlos NJ, Leong C, Kular J, Liu J, Feng X, Zheng MH, Xu J. 2009. Myocyte enhancer factor 2 and microphthalmia-associated transcription factor cooperate with NFATcl to transactivate the V-ATPase d2 promoter during RANKL-induced dosteoclastogenesis. The Journal of biological chemistry 284(6767-21): 1 .). MTS obtained the luciferase assay system from Promega, Sydney...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of kavain in preparing drug for treating osteoporosis. Impact of kavain on osteoclast differentiation, osteoclast absorption and osteoblast differentiaon is evaluated through tartrate-resistant acid phosphatase dyeing, immunofluorescence, reverse transcription-polymerase chain reaction and immunoblotting analysis. Results show that kavain inhibits RANKL inducedosteoclast by blocking NFAT and MAPK passages mediated by calcium while NF-kB is unaffected; kavain also inhibits bone resorption o osteoclast and has no obvious impact on differentiation and proliferation of osteoblast. In addition, kavain can inhibit formation of osteoclast to bone loss of ovariectomized mice. Data display that osteoclast of kavain which is a natural compound has specific effect, which shows that kavain has potential value in treating osteoporosis diseases.

Description

technical field [0001] The invention belongs to the technical field of bone disease treatment, and particularly relates to the application of tacapolin in the preparation of a drug for treating osteoporosis. Background technique [0002] Bone remodeling collectively refers to the processes of bone resorption and bone formation, and the balance between these two processes maintains normal bone homeostasis. If bone resorption exceeds bone synthesis, it is a pathological feature of osteolysis and osteoporosis. Osteoclasts are the main cells that perform the function of bone resorption. Osteoclasts are responsible for bone resorption in the process of bone remodeling. The increase in the number of osteoclasts and the enhancement of bone resorption activity are the main factors leading to osteoporosis and other related diseases. Therefore, regulating the formation and function of osteoclasts is the key to the treatment of osteoporosis and osteoporosis, and exploring the regulati...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/366A61P19/10
CPCA61K31/366A61P19/10
Inventor 徐家科赵劲民郭强曹震刘倩宋方茗
Owner GUANGXI MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap